Meeting
2018 Genitourinary Cancers Symposium
Pembrolizumab for recurrent or advanced prostate cancer.
Authors
Juliana Higa
Prostate Oncology Specialists, Marina Del Rey, CA
Juliana Higa , Kirk Wilenius , Joanne B. Weidhaas , Claire Larsen , Richard Y. Lam , Jeffrey Turner , Mark C. Scholz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 250)
DOI
10.1200/JCO.2018.36.6_suppl.250
Abstract #
250
Poster Bd #
M4
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Survival after sipuleucel-T (SIP-T) and low-dose ipilimumab (IPI) in men with metastatic, progressive, castrate-resistant prostate cancer (M-CRPC).
First Author: Justine Ku
Poster
2022 ASCO Genitourinary Cancers Symposium
Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).
First Author: Zeynep Busra Zengin
Poster
2019 Genitourinary Cancers Symposium
Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Marcus Marie Moses
Poster
2017 ASCO Annual Meeting
Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Fatima Karzai